{"id":"W2993083975","doi":"10.1016/s0140-6736(19)33041-7","title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":1213,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"AstraZeneca; Allergan; Gilead Sciences; Servier; Novartis Pharma; Newcastle University; Novo Nordisk; Abbott Laboratories; National Institute for Health and Care Research; Genentech; Arrowhead Pharmaceuticals; Coherus Biosciences; Intercept Pharmaceuticals; Alexion Pharmaceuticals; Medpace; GlaxoSmithKline; NGM Biopharmaceuticals; Birmingham Biomedical Research Centre; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb; Children's Liver Disease Foundation; Sanofi","keywords":"Obeticholic acid; Interim analysis; Medicine; Placebo; Steatohepatitis; Interim; Internal medicine; Fatty liver; Clinical trial; Disease; Alternative medicine; Political science; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.034013412443777,"score_gpt":0.3386922773004405,"score_spread":0.3046788648566636,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}